ArticleJournal of diabetes research2026
Curcumol Ameliorates Diabetic Nephropathy by Inhibiting Podocyte Ferroptosis Through the xCT/GPX4 Pathway.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumol Ameliorates Diabetic Nephropathy by Inhibiting Podocyte Ferroptosis Through the xCT/GPX4 Pathway.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDiabetic nephropathy is a leading complication of diabetes mellitus and poses a significant public health challenge. Ferroptosis has emerged as a critical pathological factor that exacerbates the progression of diabetic nephropathy. While previous studies have demonstrated the antiferroptotic effects of curcumol (Cur), its therapeutic potential in treating diabetic nephropathy, along with the underlying mechanisms, remains to be fully elucidated.
methodsTo investigate this, we established a high glucose-induced MPC-5 cell injury model. Initially, we identified the safe concentration range of curcumol. Using Western blot (WB) analysis and transcriptomic profiling, we assessed target proteins and regulatory pathways, and systematically measured ferroptosis-related biomarkers. To further explore Cur's effect on ferroptosis, we cotreated the in vitro model with the ferroptosis inhibitor Fer-1 and activator RLS3, analyzing the key pathways involved using WB and transcriptomic approaches. Additionally, we established a diabetic kidney disease (DKD) mouse model to assess the effects of Cur on renal function indicators, including serum creatinine, urea nitrogen, and 24-h urinary protein levels. Renal pathological changes and molecular markers were evaluated, and the core pathway mechanisms were validated by WB analysis.
resultsIn in vitro experiments, Cur reduced iron deposition and total iron content by downregulating TRF and NCOA4. It also inhibited ACSL4-mediated lipid peroxidation, resulting in lower levels of ROS, MDA, and 4-HNE. Additionally, Cur upregulated the expression of SLC3A2, SLC7A11, and GPX4, thereby restoring the GSH-GPX4 antioxidant system. In vivo, Cur improved renal function and alleviated renal injury in DKD mice through the xCT/GPX4 signaling pathway. These findings suggest that Cur mitigates ferroptosis via the xCT/GPX4 pathway, ultimately slowing the progression of diabetic kidney disease.
conclusionOur in vitro and in vivo experiments demonstrate that Cur has therapeutic potential for DKD. Mechanistically, Cur protects against podocyte ferroptosis by modulating the xCT/GPX4 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.